Such strategy is currently applied in phase I clinical trials in TNBC and HNSCC combining DPV-001 with OX40 or GITR, respectively, and then with blockade of the PD1/PD-L1 axis. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.